Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

NCT00591123 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00591123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00591123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
September 30, 2015
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic adenocarcinoma of gastric cardia, metastatic adenocarcinoma of the esophagus, unresectable adenocarcinoma of gastric cardia, unresectable adenocarcinoma of the esophagus